🔮 OOTWOracle · All predictions · Odds sheet · Track record · Benchmark

DEA maintains Schedule I for psilocybin/MDMA absent formal FDA approval through 2026.

Predicted 2026-07-13 · Resolves 2026-12-31 · regulatory · USA

82%

ORACLE CONFIDENCE

⏳ Pending

Every outcome is scored publicly in the ledger.

The process for moving a drug out of the most restricted federal category starts only after the FDA approves it as medicine. Since neither psilocybin nor MDMA has reached that finish line, the DEA (the Drug Enforcement Administration) has no legal mechanism to change their status in 2026. This keeps a hard ceiling on how these substances can be used, studied, and sold across most of the country.

Resolution rule: YES if, as of 2026-12-31, both psilocybin and MDMA remain listed in Schedule I with no final DEA rescheduling rule published. Check the DEA controlled-substances scheduling list and any final rules at federalregister.gov (search 'psilocybin' / 'MDMA' rescheduling). NO if either substance is moved to Schedule II–V by a final rule. Check date: 2026-12-31.

Scheduling follows FDA approval, not appropriations riders or public sentiment. No NDA for psilocybin or MDMA is pending final action, so DEA rescheduling is procedurally impossible in this window.

5 new falsifiable predictions, every day at 12:05 PM ET.

Get tomorrow's Oracle →